Inhibition of human insulin gene transcription by peroxisome proliferator-activated receptor γ and thiazolidinedione oral antidiabetic drugs

British Journal of Pharmacology

Volumn 157, Issue 5, 2009, Pages 736-745

  Schinner, S ^a,b   Kratzner R ^a   Baun, D ^a   Dickel, C ^a   Blume, R ^a   Oetjen, E ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

cells; Human insulin gene transcription; PPAR ; Thiazolidindiones

Indexed keywords

GLITAZONE DERIVATIVE; HUMAN INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; TRANSCRIPTION FACTOR PAX6;

ARTICLE; DRUG INHIBITION; GEL MOBILITY SHIFT ASSAY; GENE CONTROL; GENETIC TRANSCRIPTION; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RAT;

ADMINISTRATION, ORAL; ANIMALS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; EYE PROTEINS; GENES, REPORTER; GLUCOSE; HOMEODOMAIN PROTEINS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; MICE; MICE, TRANSGENIC; PAIRED BOX TRANSCRIPTION FACTORS; PPAR GAMMA; PROMOTER REGIONS, GENETIC; RATS; REPRESSOR PROTEINS; THIAZOLIDINEDIONES; TRANSCRIPTION INITIATION SITE; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION;

EID: 70349423273     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00208.x     Document Type: Article

References (49)

1. Beimesche S, Neubauer A, Herzig S, Grzeskowiak R, Diedrich T, Cierny I et al. (1999). Tissue-specific transcriptional activity of a pancreatic islet cell specific enhancer sequence/Pax6-binding site determined in normal adult tissues in vivo using transgenic mice. Mol Endocrinol 13: 718-728. (Pubitemid 30645325)
2. Bollheimer LC, Troll S, Landauer H, Wrede CE, Schölmerich J, Buettner R (2003). Insulin sparing effects of troglitazone in rat pancreatic islets. J Mol Endocrinol 31: 61-69. (Pubitemid 37063079)
3. Braissant O, Wahli W (1998). Differential expression of peroxisome proliferator-activated receptor-alpha, -beta, and -gamma during rat embryonic development. Endocrinology 139: 2748-2754. (Pubitemid 28512383)
4. Brunham LR, Kruit JK, Pape TD (2007). Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinediones. Nat Med 13: 340-347.
5. Desvergne B, Wahli B (1999). Peroxisome proliferators-activated receptors: nuclear control of metabolism. Endocr Rev 20: 649-688. (Pubitemid 30650602)
6. Diani AR, Peterson T, Sawada GA, Wyse BM, Gilchrist BJ, Hearron AE et al. (1984). Ciglitazone, a new hypoglycaemic agent. 4. Effect on pancreatic islets of C57BL/6J ob/ob and C57BL/KsJ-db/db mice. Diabetologia 27: 225-234.
7. Diani AR, Sawada G, Wyse B, Murray FT, Khan M (2004). Pioglitazone preserves pancreatic islets structure and insulin secretory function in three murine models of type 2 diabetes. Am J Physiol Endocrinol Metab 286: E116-E122. (Pubitemid 38036617)
8. DormandyJA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK et al. (2005). SEcondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised trial. Lancet 366: 1279-1289. (Pubitemid 41416583)
9. Fromont-Racine M, Bucchinl D, Madsen O, Desbois P, Line S, Nielsen JH et al. (1990). Effect of 5'-flanking sequence deletions on expression of the human insulin gene in transgenic mice. MoI Endocrinol 4: 669-677. (Pubitemid 20369375)
10. Gervois P, Fruchart JC, Staels B (2007). Drug insight: mechanisms of action and therapeutic applications for agonist of peroxisome proliferator-activated receptors. Nat Clin Praet Endocrinol Metab 3: 145-156. (Pubitemid 46146967)
11. Grzeskowiak R, Amin J, Oetjen E, Knepel W (2000). Insulin responsiveness of the glucagon gene conferred by interactions between proximal promoter and more distal enhancer like elements involving the paired-domain transcription factor Pax6. J Biol Chem 275: 30037-30045. (Pubitemid 30751308)
12. Hay CW, Docherty K (2006). Comparative analysis of Insulin gene promoters implications for diabetes research. Diabetes 50: 3201-3213.
13. Juhl CB, Hollingdal M, Porksen N, Prange A, Lönnqvist F, Schmitz O (2003). Influence of rosiglitazone treatment on beta-cell function in type 2 diabetes: evidence of an increased ability of glucose to entrain high-frequency insulin pulsatility. J Clin Endocrinol Metab 88: 3794-3800. (Pubitemid 37034530)
14. Kim HI, Kim JW, Kim SH, Cha JY, Kim KS, Ahn YH (2000). Identification and functional characterization of the peroxisomal proliferators response element in rat GLUT2 promoter. Diabetes 49: 1517-1524.
15. Kim HI, Cha JY, Kim SY, Kim JW, Roh KJ, Seong JK et al. (2002). Peroxisomal proliferator activated receptor-y upregulates glucokinase gene expression in β-cells. Diabetes 51: 676-685.
16. Knepel W, Jepeal L, Habener JF (1990). A pancreatic islet cell-specific enhancer-like element in the glucagon gene contains two domains binding distinct cellular proteins. J Biol Chem 265: 8725-8735. (Pubitemid 20167389)
17. Knepel W, Vallejo M, Chafitz JA, Habener JF (1991). The pancreatic islets-specific glucagon G3 transcription factors recognize control elements in the rat somatostatin and insulin 1 gene. Mol Endocrinol 5: 1457-1466.
18. Kostadinova R, Wahli W, Michalik L (2005). PPARs in diseases: control mechanisms of inflammation. Curr Med Chem 12: 2995-3009. (Pubitemid 41672488)
19. Krätzner R, Fröhlich F, Lepler K, Schröder M, Roher K, Dickel C et al. (2008). A Peroxisome proliferator-activated receptor cretinoid X receptor heterodimer physically interacts with the transcriptional activator PAX6 to inhibit glucagon gene transcription. Mol Pharmacol 73: 509-517. (Pubitemid 351159221)
20. Lago RM, Singh PP, Nesto RW (2007). Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidindiones: a meta-analysis of randomised clinical trials. Lancet 370: 1129-1136.
21. Li M, Pascual G, Glass CK (2000). Peroxisome proliferators-activated receptor gamma dependent repression of the inducible nitric oxide synthase gene. Mol Cell Biol 20: 4699-4707. (Pubitemid 30396117)
22. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE (2007). Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298: 1180-1188. (Pubitemid 47403104)
23. Lupl R, Del Guerra S, Marselli L, Bugliani M, Boggi U, Mosca F et al. (2004). Rosiglitazone prevents the impairment of human islets function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion. Am J Physiol Endocrinol Metab 286: E560-E567. (Pubitemid 38374953)
24. Melloul D, Marshak S, Cerasi E (2002). Regulation of insulin gene transcription. Diabetologia 45: 309-326.
25. Nakamichi Y, Kikuta T, Ito E, Ohara-Imaizumi M, Nishikawa C, Ishida H et al. (2003). PPAR-gamma overexpression suppresses glucoseinduced proinsulin biosynthesis and insulin release synergistically in MIN6 cells. Biochem Biophys Res Commun 306: 832-836. (Pubitemid 36776206)
26. Natali A, Ferranini E (2006). Effects of metformin and thiazolidindiones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia 49: 434-441. (Pubitemid 43277865)
27. Nissen SE, Wolski K (2007). Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457-2471. (Pubitemid 46919772)
28. Oetjen E, Baun D, Beimesche S, Krause D, Cierny I, Blume R et al. (2003a). Inhibition of human insulin gene transcription by the immunosuppressive drugs cyclosporin A and tacrolimus in primary, mature islets of transgenic mice. Mol Pharmacol 63: 1289-1295. (Pubitemid 36627223)
29. Oetjen E, Grapentin D, Blume R, Seeger M, Krause D, Eggers A et al. (2003b). Regulation of human insulin gene transcription by the immunosuppressive drugs cyclosporin A and tacrolimus at concentrations that inhibit calcineurin activity and involving the transcription factor CREB. Naunyn-Schmiedeberg's. Arch Pharmacol 367: 227-236.
30. Oetjen E, Blume R, Cierny I, Schlag C, Kutschenko A, Krätzner R et al. (2007). Inhibition of MafA transcriptional activity and human insulin gene transcription by interleukin-1ß and mitogen-activated protein kinase kinase kinase in pancreatic islet beta cells. Diabetologia 50: 1678-1687.
31. Ovalle F, Bell DS (2004). Effect of rosiglitazone versus insulin on the pancreatic beta-cell function of subjects with type 2 diabetes. Diabetes Care 27: 2585-2589. (Pubitemid 39441455)
32. Reichardt HM, Kaestner KH, Tuckermann J, Kretz O, Weesely O, Bock R et al. (1998). DNA binding of the glucocortiocid receptor is not essential for survival. Cell 93: 531-541. (Pubitemid 28240715)
33. Richardson H, Campbell SC, Smith SC, Macfarlane WM (2006). Effects of rosiglitazone on pancreatic beta cell gene expression. Diabetologia 49: 685-696. (Pubitemid 43357542)
34. Ricote M, Huang J, Fajas L, Welch J, Najib J, Witzum JL et al. (1998). Expression of the peroxisome proliferator activated receptor gamma (PPARγ) in human artherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA 95: 7614-7619. (Pubitemid 28293301)
35. -1) glucose. J Clin Endocrinol Metab 89: 795-805.
36. Rosen ED, Kulkarni RN, Sarraf P, Ozean U, Okada T, Hsu T et al. (2003). Targeted elimination of peroxisome proliferator-activated receptor γ in ß cells leads to abnormalities in islet mass without compromising glucose homeostasis. Mol Cell Biol 23: 7222-7229. (Pubitemid 37214026)
37. Sander M, Neubüser A, Kalamaras J, Ee HC, Martin GR, German MS (1997). Genetic analysis reveals that PAX6 is required for normal transcription of pancreatic hormone genes and islet development. Genes Devil: 1662-1673. (Pubitemid 27300592)
38. Santerre RF, Cook RA, Crisel RM, Sharp JD, Schmidt RJ, Williams DC et al. (1981). Insulin synthesis in a clonal cell line of simian virus 40-transformed hamster pancreatic ß cells. Proc Natl Acad Sci USA 78:4339-4343.
39. Schinner S, Dellas C, Schröder M, Heinlein CA, Chang C, Fischer J et al. (2002). Repression of glucagon gene transcription by peroxisome proliferator-activated receptor y through inhibition of Pax6 transcriptional activity. J Biol Chem 277: 1941-1948. (Pubitemid 34968772)
40. Schwaninger M, Lux G, Blume R, Oetjen E, Hidaka H, Knepel W (1993). Membrane depolarisation and calcium influx induce glucagon gene transcription in pancreatic islet cells through cyclic AMPresponsive element. J Biol Chem 268: 5168-5177. (Pubitemid 23081645)
41. Siemann G, Blume R, Grapentin D, Oetjen E, Knepel W (1999). Inhibition of cyclic AMP response element-binding protein/cyclic AMP response element-mediated transcription by the immunosuppressive drugs cyclosporin A and FK506 depends on the promoter context. Mot Pharmacol 55: 1094-1100. (Pubitemid 29252377)
42. Singh S, Lke YK, Furberg CD (2007). Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298: 1189-1195. (Pubitemid 47403105)
43. St-Onge L, Sosa-Pineda B, Chowdhury K, Mansouri A, Gruss P (1997). Pax6 is required for differentiation of glucagon-producing a-cells in mouse pancreas. Nature 387: 406-409. (Pubitemid 27227205)
44. Tuckermann JP, Reichardt HM, Arribas R, Richter KH, Schütz G, Angel P (1999). The DNA binding-independent function of the glucocorticoid receptor mediates repression of AP-1-dependent genes in skin. J Cell Biol 147: 1365-1370. (Pubitemid 30027391)
45. Vandewalle B, Moerman E, Lefebvre B, Defrance F, Gmyr V, Lukowiak B et al. (2008). PPARγ-dependent and-independent effects of rosiglitazone on lipotoxic human pancreatic islets. Biochem Biophys Res Commun 366: 1096-1101.
46. Wajchenberg BL (2007). β-cells failure in diabetes and preservation by clinical treatment. Endocr Rev 28: 187-218. (Pubitemid 46984834)
47. Walter H, Lübben G (2005). Potential role of oral thiazolidindione therapy in preserving beta cell function in type 2 diabetes mellitus. Drugs 65: 1-13. (Pubitemid 40143799)
48. Yildiz N, Diedrich T, Knepel W (1996). Nuclear protein binding and functional activity of a variant insulin gene found in non-insulindependent diabetes mellitus. Exp Clin Endocriinol Diabetes 104: 218-227. (Pubitemid 26225988)
49. Zeender E, Maedler K, Bosco D, Berney T, Donath MY, Halban PA (2004). Pioglitazone and sodium salicylate protect human beta-cells against apoptosis and impaired function induced by glucose and interleukin-1beta. J Clin Endocrinol Metab 89: 5059-5066. (Pubitemid 39391449)